Correlation Between Vicore Pharma and IRLAB Therapeutics

Can any of the company-specific risk be diversified away by investing in both Vicore Pharma and IRLAB Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vicore Pharma and IRLAB Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vicore Pharma Holding and IRLAB Therapeutics AB, you can compare the effects of market volatilities on Vicore Pharma and IRLAB Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vicore Pharma with a short position of IRLAB Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vicore Pharma and IRLAB Therapeutics.

Diversification Opportunities for Vicore Pharma and IRLAB Therapeutics

0.51

Correlation Coefficient

Vicore Pharma  IRLAB Therapeutics

Very weak diversification

The 3 months correlation between Vicore and IRLAB is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Vicore Pharma Holding and IRLAB Therapeutics AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on IRLAB Therapeutics and Vicore Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vicore Pharma Holding are associated (or correlated) with IRLAB Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of IRLAB Therapeutics has no effect on the direction of Vicore Pharma i.e., Vicore Pharma and IRLAB Therapeutics go up and down completely randomly.

Pair Corralation between Vicore Pharma and IRLAB Therapeutics

Assuming the 90 days trading horizon Vicore Pharma Holding is expected to generate 0.55 times more return on investment than IRLAB Therapeutics. However, Vicore Pharma Holding is 1.82 times less risky than IRLAB Therapeutics. It trades about 0.05 of its potential returns per unit of risk. IRLAB Therapeutics AB is currently generating about -0.16 per unit of risk. If you would invest  759.00  in Vicore Pharma Holding on April 24, 2025 and sell it today you would earn a total of  61.00  from holding Vicore Pharma Holding or generate 8.04% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Vicore Pharma Holding  vs.  IRLAB Therapeutics AB

Vicore Pharma Holding

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Vicore Pharma Holding are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Vicore Pharma may actually be approaching a critical reversion point that can send shares even higher in August 2025.

IRLAB Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days IRLAB Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Vicore Pharma and IRLAB Therapeutics

The main advantage of trading using opposite Vicore Pharma and IRLAB Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vicore Pharma position performs unexpectedly, IRLAB Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IRLAB Therapeutics will offset losses from the drop in IRLAB Therapeutics' long position.

The idea behind Vicore Pharma Holding and IRLAB Therapeutics AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.